v3.26.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Profit or Loss and Significant Segment Expenses Additional information about segment profit or loss and significant segment expenses is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Direct R&D program expense
BHV-4157 (Troriluzole)$1,300 $10,769 $15,926 $38,802 
BHV-2000 (Taldefgrobep Alfa)6,354 4,489 21,417 18,719 
BHV-7000 & BHV-7010 (Kv7)19,295 29,671 52,873 92,415 
BHV-2100 & BHV-2110 (TRPM3 Antagonist)
(1,178)2,720 (1,708)26,314 
BHV-8000 (TYK2/JAK1)4,208 4,134 13,520 29,722 
BHV-1300 (IgG Degrader)9,818 8,628 20,821 28,980 
BHV-1310 (IgG Degrader)(149)369 (168)5,055 
BHV-1400 (IgA Degrader)10,067 8,049 26,913 19,646 
BHV-1600 (β1-AR AAB Degrader)29 1,977 (70)6,786 
BHV-1510 (TROP-2)
2,166 9,327 8,668 19,200 
BHV-1530 (FGFR3)2,576 2,437 5,985 21,006 
Other R&D program expense9 562 72 2,177 
Preclinical research programs R&D Expense
12,239 16,675 28,518 58,608 
R&D personnel expense (excluding share-based compensation)(1)
18,234 20,473 58,667 62,100 
R&D Share-based compensation expense
12,066 13,947 42,524 62,291 
G&A personnel expense (excluding share-based compensation)(1)
5,819 6,276 17,039 18,755 
G&A Share-based compensation expense
6,558 7,588 23,550 33,118 
Other segment items (2)
17,009 21,291 47,200 58,950 
Non-operating expense (income)2,923 3,840 14,776 (10,468)
(Benefit) provision for income taxes(64)221 599 1,091 
Segment net loss
129,279 173,443 397,122 593,267 
Reconciliation of profit or loss
Adjustments and reconciling items
— — — — 
Consolidated net loss
$129,279 $173,443 $397,122 $593,267 
(1)    Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other.
(2)    Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.